VEGFA contributes to the malignant processes in LC by inducing angiogenesis, growth, invasion, prosurvival, metastasis, lymphangiogenesis, and migration of LC cells and tumors, and its expression and polymorphisms are related to the therapeutic responsiveness, prognosis, and cancer susceptibility of patients with LC [108–113]. Here, VEGFA is linked to laryngotracheoesophageal cleft.